Overview

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses (6 Days) of 100 mg Resmetirom in Subjects With Severe Renal Impairment and in Matched Healthy Control Subjects With Normal Renal Function

Status:
ENROLLING_BY_INVITATION

Trial end date:
2024-12-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to directly characterize the pharmacokinetic (PK) profiles of resmetirom and its major metabolite (MGL-3623) following oral administration of 100 mg resmetirom (QD x 6 days) in subjects with severe renal impairment (RI) compared to healthy matched control subjects with normal renal function.

Phase:

PHASE1

Details

Lead Sponsor:

Madrigal Pharmaceuticals, Inc.

Treatments:

resmetirom